ANAVEX LIFE SCIENCES CORP.
ANAVEX LIFE SCIENCES CORP. (AVXL): 4 pipeline candidates · ~55 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
55.3 months
D/E 0.05 · 0% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for ANAVEX LIFE SCIENCES CORP.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$231.7M
Cash
$131.7M
Quarterly Burn
$7.2M
Runway
55.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| ANAVEX® 2-73 (blarcamesine) | Phase 2 |
| ANAVEX® 3-71 (AF710B) | Phase 2 |
| ANAVEX®2-73 | Phase 3 |
| ANAVEX®3-71 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
191
Total value held
$135.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 7,727,900 | $23.7M |
| blackrock, inc. | 7,609,618 | $23.4M |
| state street corp | 4,512,028 | $13.9M |
| two sigma investments, lp | 3,247,888 | $10.0M |
| geode capital management, llc | 2,188,275 | $6.7M |
| susquehanna international group, llp | 1,539,563 | $4.7M |
| citadel advisors llc | 1,172,035 | $3.6M |
| bank of america corp /de/ | 863,150 | $2.6M |
| goldman sachs group inc | 804,435 | $2.5M |
| vanguard portfolio management llc | 783,148 | $2.4M |
Showing top 10 of 191 institutional holders of ANAVEX LIFE SCIENCES CORP.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ANAVEX LIFE SCIENCES CORP.'s pipeline?
ANAVEX LIFE SCIENCES CORP. (AVXL) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ANAVEX LIFE SCIENCES CORP.'s lead drug candidate?
ANAVEX LIFE SCIENCES CORP.'s most advanced tracked candidate is ANAVEX® 2-73 (blarcamesine) (Phase 2) for Alzheimer's disease; Rett syndrome; Parkinson's disease dementia; Parkinson's disease.
What is ANAVEX LIFE SCIENCES CORP.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ANAVEX LIFE SCIENCES CORP. has approximately 55.3 months of cash runway.
What is ANAVEX LIFE SCIENCES CORP.'s market capitalization?
ANAVEX LIFE SCIENCES CORP.'s market capitalization is approximately $231.7M.
Who is the CEO of ANAVEX LIFE SCIENCES CORP.?
Dr. Terrie Kellmeyer Ph.D. is the chief executive officer of ANAVEX LIFE SCIENCES CORP. (AVXL).
Get the full picture on ANAVEX LIFE SCIENCES CORP.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.